Gestrin-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed to manage gastrointestinal disorders characterized by acid-related symptoms and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these agents in Gestrin-DSR Capsule offers comprehensive management of upper gastrointestinal symptoms by addressing both acid hypersecretion and impaired gastric motility. This combination is particularly beneficial in patients with refractory GERD or functional dyspepsia where monotherapy may be insufficient. Gestrin-DSR should be administered as prescribed by a healthcare professional, with consideration of contraindications such as known hypersensitivity to either component, and caution in patients with cardiac arrhythmias or electrolyte imbalances. Regular monitoring is advised to ensure therapeutic efficacy and minimize potential adverse effects.